STAT3 and Alzheimer disease: Although JAK inhibition can have adverse side effects [50,51], strategies to specifically target STAT3 with small molecules have been effective in preclinical models of Alzheimer’s disease [32,52] and may provide alternatives for reducing GFAP pathology in AxD.